MECHANISMS FOR KETOAMIDE ESCAPE IN VAL55 VARIANTS OF THE HCV NS3/4A PROTEASE DOMAIN

被引：0
|
作者：
Welsch, C. [1 ,2 ,3 ]
Schweizer, S. [4 ,5 ]
Shimakami, T. [3 ]
Antes, I. [4 ,5 ]
Zeuzem, S. [1 ]
Lemon, S. [3 ]
机构：
[1] Goethe Univ Frankfurt, Med Klin 1, Frankfurt, Germany
[2] Max Planck Inst Informat, Saarbrucken, Germany
[3] Univ N Carolina, Chapel Hill, NC USA
[4] Tech Univ Munich, Munich, Germany
[5] Kanazawa Univ, Kanazawa, Ishikawa, Japan
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61226-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1214
引用
收藏
页码：S482 / S482
页数：1
相关论文
共 50 条
  • [41] Process development of ABT-450-A first generation NS3/4A protease inhibitor for HCV
    Caspi, Daniel D.
    Cink, Russell D.
    Clyne, Dean
    Diwan, Moiz
    Engstrom, Kenneth M.
    Grieme, Timothy
    Mei, Jianzhang
    Miller, Robert W.
    Mitchell, Clifford
    Napolitano, Jose G.
    Nere, Nandkishor
    Ravn, Matthew M.
    Sheikh, Ahmad
    Wagaw, Seble
    Zhang, Hongqiang
    TETRAHEDRON, 2019, 75 (32) : 4271 - 4286
  • [42] Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups
    Venkatraman, Srikanth
    Velazquez, Francisco
    Wu, Wanli
    Blackman, Melissa
    Madison, Vincent
    Njoroge, F. George
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (07) : 2151 - 2155
  • [43] Inhibitors of hepatitis C virus NS3•4A protease:: P2 proline variants
    Farmer, LJ
    Britt, SD
    Cottrell, KM
    Court, JJ
    Courtney, LF
    Deininger, DD
    Gates, CA
    Harbeson, SL
    Lin, K
    Lin, C
    Luong, YP
    Maxwell, JP
    Pitlik, J
    Rao, BG
    Schairer, WC
    Thomson, JA
    Tung, RD
    Van Drie, JH
    Wei, YY
    Perni, RB
    LETTERS IN DRUG DESIGN & DISCOVERY, 2005, 2 (07) : 497 - 502
  • [44] A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches
    Ezat, Ahmed A.
    Elshemey, Wael M.
    LIFE SCIENCES, 2019, 217 : 176 - 184
  • [45] Crowded environment affects the activity and inhibition of the NS3/4A protease
    Popielec, Agnieszka
    Ostrowska, Natalia
    Wojciechowska, Monika
    Feig, Michael
    Trylska, Joanna
    BIOCHIMIE, 2020, 176 : 169 - 180
  • [46] Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
    Sivi Ouwerkerk-Mahadevan
    Jan Snoeys
    Monika Peeters
    Maria Beumont-Mauviel
    Alexandru Simion
    Clinical Pharmacokinetics, 2016, 55 : 197 - 208
  • [47] Molecular docking study of P4-Benzoxaborole-substituted ligands as inhibitors of HCV NS3/4A protease
    Wadood, Abdul
    Riaz, Muhammad
    Jamal, Syed Babar
    Shah, Masaud
    Lodhi, Muhammad Arif
    BIOINFORMATION, 2013, 9 (06) : 309 - 314
  • [48] Mechanistic role of NS4A and substrate in the activation of HCV NS3 protease
    Zhu, Haimei
    Briggs, James M.
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2011, 79 (08) : 2428 - 2443
  • [49] PRECLINICAL PROFILE OF THE PAN-GENOTYPIC HCV NS3/4A PROTEASE INHIBITOR GS-9857
    Taylor, J. G.
    Appleby, T.
    Barauskas, O.
    Chen, X.
    Dvory-Sobol, H.
    Gong, R.
    Lee, J.
    Nejati, E.
    Schultz, B.
    Wang, Y.
    Yang, C.
    Yu, M.
    Zipfel, S.
    Chan, K.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S681 - S681
  • [50] Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity
    Jittavisutthikul, Surasak
    Seesuay, Watee
    Thanongsaksrikul, Jeeraphong
    Thueng-in, Kanyarat
    Srimanote, Potjanee
    Werner, Rolf G.
    Chaicumpa, Wanpen
    FRONTIERS IN IMMUNOLOGY, 2016, 7
12345